Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Bayer Ag Ord (OP:BAYZF)

43.02 -0.32 (-0.73%)

Streaming Delayed Price Updated: 1:57 PM EST, Dec 31, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	518
Open	42.50
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	43.33
Today's Range	42.50 - 43.02
52wk Range	19.55 - 43.48
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

December 04, 2025

From Bayer

Via Business Wire

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

December 03, 2025

From Bayer

Via Business Wire

Performance

YTD	N/A	N/A
1 Month	+21.5%	+21.5%
3 Month	+26.5%	+26.5%
6 Month	+37.9%	+37.9%
1 Year	+117.5%	+117.5%

More News

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

December 02, 2025

From Bayer

Via Business Wire

Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations

December 01, 2025

From Bayer

Via Business Wire

Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention

November 23, 2025

From Bayer

Via Business Wire

U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

November 20, 2025

From Bayer

Via Business Wire

Agricultural Conglomerate Bayer Confident In Long-Term Outlook Despite Litigation Risks ↗

November 12, 2025

Via Benzinga

Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science

November 10, 2025

From Bayer

Via Business Wire

KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease

November 06, 2025

From Bayer

Via Business Wire

Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause

October 24, 2025

From Bayer

Via Business Wire

Late-breaking data from Phase III OCEANIC-STROKE study accepted for presentation at World Stroke Congress 2025

October 21, 2025

From Bayer

Via Business Wire

Bayer Partners with Cornfed Farms to Create First ForwardFarm in Midwest

October 07, 2025

From Bayer

Via Business Wire

One A Day® Unveils Bold New Brand Identity and Platform: “The ONE for you”

October 07, 2025

From Bayer

Via Business Wire

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

October 07, 2025

From Bayer

Via Business Wire

Bayer Selects Interpublic as Global Media, Production and Creative Agency Partner for Consumer Health Division

September 29, 2025

From Bayer

Via Business Wire

Bayer to Highlight New Data for KERENDIA® (finerenone) at Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025

September 25, 2025

From Bayer

Via Business Wire

Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease

September 22, 2025

From Bayer

Via Business Wire

10 Years of Supporting Rural America: Bayer and Luke Bryan Team Up with Feeding America® to Tackle Hunger with “Take Care, Now” Campaign

September 15, 2025

From Bayer

Via Business Wire

Gadoquatrane New Drug Application Accepted for Review by U.S. FDA

August 27, 2025

From Bayer

Via Business Wire

Monsanto Reaches Agreements in Principle to Resolve Additional PCB Cases at the Sky Valley Education Center

August 18, 2025

From Bayer

Via Business Wire

Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market

August 15, 2025

From Bayer

Via Business Wire

OTC Markets Group Welcomes Bayer AG to OTCQX

May 23, 2025

From OTC Markets

Via GlobeNewswire

Bayer Shares Fall 7% As US Court Reconsiders Monsanto PCB Exposure Case ↗

October 09, 2024

Via Talk Markets

Futures Rally Fizzles As Dollar, Yields And Oil Slump ↗

August 17, 2024

Via Talk Markets

Bayer Weedkiller Lawsuit Dismissed By Australian Judge: Insufficient Evidence Linking Roundup To Blood Cancer ↗

July 25, 2024

Via Benzinga

Frequently Asked Questions

Is Bayer Ag Ord publicly traded?

Yes, Bayer Ag Ord is publicly traded.

What exchange does Bayer Ag Ord trade on?

Bayer Ag Ord trades on the OTC Traded

What is the ticker symbol for Bayer Ag Ord?

The ticker symbol for Bayer Ag Ord is BAYZF on the OTC Traded

What is the current price of Bayer Ag Ord?

The current price of Bayer Ag Ord is 43.02

When was Bayer Ag Ord last traded?

The last trade of Bayer Ag Ord was at 12/31/25 01:57 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.